Left ventricular hypertrophy (LVH) is predictive of cardiovascular disease. The vasodilator, natriuretic and diuretic actions of atrial natriuretic peptide (ANP) support a role in the pathophysiology of hypertension. Measuring the redundant precursor fragment mid-regional portion of pro-atrial natriuretic peptide (MRproANP) overcomes the technical difficulties of quantifying the bioactive ANP. This study sought to investigate the diagnostic and prognostic utility of MRproANP in a hypertensive Caucasian patient population. A total of 194 hypertensive patients (39 patients with LVH, 69 ± 7.82 years of age, 74% female vs 155 patients without LVH, 68±6.51 years of age, 71% female) were derived from a screening study. Plasma MRproANP concentrations were quantified using immunoluminometric assays. Hypertensive patients with LVH had higher MRproANP concentrations than those without LVH (103.04 (50.58) vs 84.11 pmol l --1 (44.82); P ¼ 0.014). Independent predictors of left ventricular mass index were LogMRproANP (P ¼ 0.022), male gender (Po0.001), body mass index (P ¼ 0.001) and history of angina or myocardial infarction (P ¼ 0.009). The receiver operating curve for MRproANP for the detection of LVH was limited, yielding an area under the curve of only 0.628 (confidence interval 0.523 --0.733; P ¼ 0.014). Therefore, the role of MRproANP may not lie in the diagnosis of LVH but in monitoring the response to therapy. A nonsignificant trend towards greater mortality in patients with above-median MRproANP levels compared with below-median levels (P ¼ 0.167) was observed. Larger studies are required to assess its prognostic utility further.
INTRODUCTION
Left ventricular hypertrophy (LVH) is a manifestation of uncontrolled arterial hypertension. It is an adverse marker of target endorgan damage, predictive of cardiovascular morbidity and mortality. 1 Early detection of LVH is of great importance as its regression is associated with improved prognosis in hypertensive patients independent of ambulatory blood pressure. 2 Hypertension involves the complex interplay of various vasoactive peptides. There is growing interest to better understand if these vasoactive peptides play a role in the pathogenesis of LVH and whether they can be used as potential screening tools for the detection of LVH in the community. Their use as surrogate markers of LVH could potentially aid the titration of drug therapy.
Natriuretic peptides show the most promise in detecting LVH. The vasodilator, natriuretic and diuretic properties of the natriuretic hormones support a role in the pathophysiology of hypertension. 3 Nishikimi et al. 4 showed that the natriuretic peptides are raised in hypertensive patients compared with normotensive patients. There is however contradictory information regarding the diagnostic utility of atrial natriuretic peptide (ANP) in hypertension. A study by Zachariah et al. 5 showed that plasma ANP levels were not elevated in patients with uncomplicated essential hypertension. Furthermore, a recent study by Partanen et al. 6 reported that ANP failed to discriminate LVH determined by magnetic resonance imaging in patients with stage 1 hypertension. These differences in diagnostic utility may be related to differences in assay design. The bioactive ANP has a short half-life and is unstable, and therefore assays may underestimate its true plasma concentration. This has led to the adoption of the mid-regional portion of pro-ANP (MRproANP) that is more stable in plasma and resistant to the exoproteases unlike the N-and C-terminals. 7 A study by Khaleghi et al. 8 reported that in hypertensive African Americans, MRproANP levels were associated with lower ankle brachial pressure index and greater LV mass index. In non-Hispanic white hypertensive patients, MRproANP concentrations were not significantly associated with urinary albumin creatinine ratio after adjustment for age and gender. No echocardiographic data were present for the nonHispanic white hypertensive cohort of this study. 8 The objectives of our study were first to investigate the diagnostic performance of MRproANP in comparison with N-terminal proB-type natriuretic peptide (NTproBNP) in the detection of LVH in a hypertensive Caucasian patient population, and second to determine whether MRproANP influences prognosis in hypertensive patients.
MATERIALS AND METHODS

Study population
Hypertensive patients were derived from a local screening study. Medical records were reviewed and information pertaining to a history of ischaemic heart disease (myocardial infarction (MI) or angina), hypertension, diabetes mellitus, smoking history and cardiovascular medication were collected. This study complied with the Declaration of Helsinki Principles and had local ethical approval. Patients gave written informed consent for their participation in the study. Patients consented for physical examination, venepuncture and echocardiography. A set of exclusion criteria were developed, limited to patients with secondary causes of hypertension, history of heart failure and those with echocardiographic abnormalities (valvular disease). Systolic and diastolic blood pressure was measured three times at 5-min intervals. Treated hypertensive patients were not required to stop their antihypertensive medication before entering into the study. The MDRD (Modification of Diet and Renal Disease) formula was used to calculate the estimated glomerular filtration rate of the patients. 9 End points Death from cardiovascular disease was used as an end point. Outcome data were obtained from hospital records.
Electrocardiographic (ECG) criteria for LVH
LVH was defined as a Sokolow --Lyon voltage criteria of SV 1 þ RV 5 or RV 6 43.5 mv. 10 
Blood sampling
Venesection was performed in recumbent volunteers. Blood samples were collected in pre-chilled tubes containing EDTA and aprotinin. Plasma was stored at À70 1C until assay and all analyses were done in a single batch. Samples for measuring plasma creatinine were collected in tubes containing lithium and heparin.
Echocardiography
Transthoracic echocardiography was performed on patients using a Sonos 5500 instrument (Philips Medical Systems, Reigate, Surrey, UK). LV ejection fraction was calculated using the biplane method of discs formula.
11 LV mass was calculated using the Devereux et al. 12 formula and indexed for body surface area to obtain LV mass index. LVH is diagnosed when the LV mass index is 4134 g m --2 or 110 g m --2 in males or females, respectively.
13
One experienced physician performed the examination and reading of images.
MRproANP assay
MRproANP concentrations were quantified using a novel noncompetitive immunoluminometric assay, reported previously. 14. The capture antibody consisted of purified sheep polyclonal antibodies directed against aminoacid sequences 73 --90 of proANP that was used to coat the test tubes. The tracer represented acridinium ester-labelled purified sheep antibody raised against the amino-acid sequences 53 --72 of proANP. The immunoassay was conducted by incubating 50 ml of sample/standard and 200 ml of tracer in the coated tubes for 30 min at room temperature. Tubes were washed with wash solution and bound chemiluminescence was measured on a LB952T luminometer (Berthold, Bad Wildbad, Germany). The limit of detection was 6.0 pmol l --1 and the intra-assay coefficient of variation was o10% for samples containing 23 --3000 pmol l --1 . The interassay coefficient of variation was 10% for a concentration of 65 pmol l --1 .
14 NTproBNP assay
Plasma NTproBNP concentrations were quantified using a noncompetitive immunoassay. 15 The capture antibody consisted of monoclonal mouse antibody directed against the C-terminal of NTproBNP that was used to coat the wells. The tracer consisted of affinity purified biotinylated sheep antibody directed against the N-terminal of human NTproBNP. Samples or NTproBNP standards were incubated in C-terminal IgG-coated wells with the biotinylated antibody for 24 h at 4 1C. Detection was with methylacridinium ester-labelled streptavidin. The lower limit of detection was 0.3 pmol l --1 . There was no crossreactivity with ANP, B-type natriuretic peptide or C-type natriuretic peptide.
Statistical analysis
Statistical analysis was performed using Statistics Package for Social Sciences version 18.0 (SPSS Inc., Chicago, IL, USA). The power of the study was calculated using Stata 11 statistical package. The study had 80.71% power (Po0.05) to detect a standardized difference of 0.4 between the LVH and non-LVH groups. Plasma MRproANP and NTproBNP concentrations were log transformed before statistical analyses. Mann --Whitney U-test was used to compare two independent groups as the continuous variable had a non-Gaussian distribution. The w 2 tests were used to compare the proportion between two categorical groups. Spearman's correlation coefficients were used to investigate the influence of LV mass index on the patient characteristics in univariate analyses. The stepwise linear regression model was used to analyse the interaction of multiple independent variables on LV mass index. To assess the diagnostic performance of MRproANP for the detection of LVH, receiver operating characteristic (ROC) curves were generated and the area under the curves (AUC) was calculated. A Kaplan --Meier curve was used to analyse survival outcomes. A P-value of o0.05 was deemed to be statistically significant.
RESULTS
The demographic data for the 194 hypertensive patients are presented in Table 1 , stratified according to the presence or absence of LVH. Both groups were comparable in age, gender and comorbidities. Body mass index (BMI) was significantly higher in the LVH group than in those without LVH (29.51 (5.57) vs 27.18 kg m --2 (4.38), P ¼ 0.013, respectively). Mean plasma concentrations of MRproANP were higher in patients with LVH than in those without LVH (103.04 (50.58) vs 84.11 pmol l --1 (44.82), P ¼ 0.014, respectively). There was no significant difference in plasma NTproBNP concentration between patients with or without LVH.
Hypertensive patients with LVH were further split into mild, moderate and severe LVH tertiles to demonstrate the trend in MRproANP levels. Plasma MRproANP concentrations increased with the increasing severity of LVH tertiles; however, there was no overall significant difference between the tertiles and between the individual tertiles in post hoc pairwise comparisons (P ¼ 0.517; Figure 1 ). Spearman's Rho correlations between LV mass index and the variables are presented in Table 2 . LV mass index was positively related with systolic blood pressure (R s ¼ 0.151, P ¼ 0.037). BMI was positively correlated with LV mass index (R s ¼ 0.238, P ¼ 0.001). An inverse relationship was observed between heart rate and LV mass index (R s ¼ À0.150, P ¼ 0.038). Both plasma MRproANP and NTproBNP concentrations were correlated with LV mass index (R s ¼ 0.200, P ¼ 0.005; R s ¼ 0.167, P ¼ 0.020, respectively).
Univariate analysis
Multivariate analysis Significant variables in univariate analyses were used as covariates in the stepwise linear regression to identify predictors of LV mass index in hypertensive patients. Variables entered into the model included male gender, systolic blood pressure, BMI, heart rate, history of angina or MI, drug therapy (b-blocker, calcium channel antagonist, thiazide diuretic), LVH ascertained by ECG, LogMRproANP and LogNTproBNP. Linear regression revealed that male gender (Po0.001), BMI (P ¼ 0.001) and history of angina or MI (P ¼ 0.009) and LogMRproANP (P ¼ 0.022) were independently predictive of LV mass index ( Table 3 ). The adjusted r 2 for the linear regression model was 18.7%.
Performance characteristics of MRproANP for detecting LVH
The ROC curve for MRproANP for the detection of LVH is presented in Figure 2 MRproANP as an indicator of LVH was 87.60 pmol l --1 . The corresponding sensitivity and specificity were 62% and 66%, respectively. In contrast, the ROC curve for NTproBNP was not significantly different from the diagonal (AUC 0.596 (confidence interval 0.491 --0.702); P ¼ 0.064).
Follow-up
The mean length of follow-up was 3001±614 days. During followup, a total of 15 patients died from cardiovascular causes. There was a trend towards greater mortality in patients with abovemedian MRproANP levels compared with below-median levels (10 vs 5 deaths); however, the difference was not statistically significant (P ¼ 0.167; Figure 3 ).
DISCUSSION
LVH is a risk factor for cardiovascular disease. The Losartan Intervention For Endpoint reduction in hypertension (LIFE) study emphasised the importance of blood pressure control and the associated prognostic benefit in regression of LVH. 16 The measurement of vasoactive peptides may be used as a screening tool for the detection of LVH in the general population setting. Also, such tools may be used to guide the titration of antihypertensive therapies. Interestingly, Zachariah et al. 5 showed that treatment with a calcium channel blocker in a hypertensive cohort reduced ANP concentrations; however, this field clearly requires further research and validation.
In this study we sought to analyse the bioactive ANP by measuring a more stable fragment stemming from the same precursor, namely MRproANP. The stoichiometric generation of MRproANP with ANP allows it to be used as a surrogate marker of the ANP system. Plasma MRproANP levels were elevated in hypertensive patients with LVH compared with those patients without. A possible explanation for this is that LVH reduces the myocardial compliance, which transmits pressure to the left atrium, thereby promoting atrial stretch. Arial stretch is a prime stimulus for ANP secretion, mediating vasodilation, diuresis and natriuresis, causing a compensatory fall in blood pressure. 4 LVH is a false dichotomy, and hence even in patients with hypertension without LVH, elevated levels of MRproANP may be an early indicator of reduced ventricular compliance. Raised levels of ANP may serve to protect the circulatory system and maintain cardiorenal homeostasis.
In our study we used LV mass index as a measure of end-organ target damage in hypertension and found that male gender, BMI, history of angina or MI and LogMRproANP concentrations were independent predictors of LV mass index after controlling for confounding variables. In comparison, Khaleghi et al. 8 used urinary albumin creatinine ratio as a measure of end-organ target damage and found that in whites, higher MRproANP levels were significantly associated with higher urinary albumin creatinine ratio. However, after adjusting for the confounding variables, the association no longer existed. This lack of association can be put down to the absence of echocardiographic data for this cohort and the different mechanism of release for MRproANP.
The MRproANP concentrations in our hypertensive cohort were higher than in Khaleghi et al. 8 study. This may be related to differences in selection criteria. However, as all assays were done in one batch, our data should be internally consistent.
MRproANP was predictive of LV mass index in the multivariate analyses, whereas despite its association with LV mass index in univariate analyses, NTproBNP failed to be predictive in the multivariate model. This study has shown that MRproANP is predictive of LV mass index in hypertensive Caucasian patients; however, the diagnostic utility of this marker for the detection of LVH is limited. The ROC curve for MRproANP yielded an AUC of 0.62. This is comparable with findings by Khaleghi et al. 8 who reported that MRproANP yielded an AUC between 0.60 and 0.66 for parameters of target end-organ damage in hypertensive African-American patients. We agree with the suggestion from Khaleghi et al. 8 that the role of MRproANP may not lie in the diagnosis of LVH but in monitoring the response to therapy.
The adjusted r 2 for our multivariate model was 18.7%, and therefore the model can only explain 18.7% of the variance in LV mass index. This highlights that although we have made some advancement in understanding this pathophysiological state, we are not able to fully explain it. Further studies investigating the genomics or proteomics may prove useful in explaining the remainder of the variance. This may help to understand the intricate interplay of genes and proteins in determining the phenotype.
Hypertensive patients with MRproANP levels above the median showed a trend towards greater mortality compared with those with levels below the median; however, the difference was not statistically significant. The lack of statistical significance may be a reflection of the small sample size, and much larger studies are needed to confirm the prognostic utility of MRproANP in hypertensive patients.
This was a single-centre study and further multicentre studies would be required to replicate and validate these finding so that they can be generalised to a wider population. The remit of this study was not to determine causality but simply to demonstrate trends. Further studies are required to establish the underlying mechanisms. The lack of information relating to stage of hypertension may be considered a limitation.
What is known about this topic
MRproANP is related with parameters of target end-organ damage; lower ankle brachial pressure index (ABPI) and greater LV mass index in hypertensive African Americans. 8 What this study adds This study revealed that MRproANP was independently predictive of LV mass index in Caucasian hypertensive patients. The diagnostic utility of this marker for the detection of LVH is limited as the ROC curve for MRproANP yielded an AUC of 0.62. Therefore, the role of MRproANP may not lie in the diagnosis of LVH but in monitoring the response to therapy.
